The important number is not 48,000, although that is how many active pharmacies Outcomes says sit in its connected network. It is not even 130 million, the patient population the company says that network can reach. The number that explains the business is $93 million. In the first six months of 2025, more than 170,000 pharmacists and technicians used the Outcomes network to complete 6.5 million medication therapy services. Pharmacies collected roughly $93 million in service and validation fees for doing the work.
That is a useful answer to the question haunting the American drugstore: what comes after the prescription margin gets squeezed? Outcomes' answer is clinical work, delivered by the person standing behind the same counter where the patient already appears. A pharmacist reviews a medication list, spots an adherence problem, calls a prescriber, discusses a vaccine or helps a patient begin a therapy. The platform finds the opportunity, puts it into workflow, documents the result and helps move payment back to the pharmacy.
What it actually doesThe screen behind the counter
Outcomes is a pharmacy technology company, but that description is too tidy. It sells the systems that process prescriptions - Rx30 and Computer-Rx - alongside patient messaging, telepharmacy, pill counting, vaccine reporting, claims reconciliation, specialty-pharmacy tools, analytics and a clinical platform. Health plans and pharmaceutical manufacturers can sponsor programs through the network. Pharmacists see eligible patients and suggested actions while doing their normal work.
The clinical engine carries more than 600 types of targeted interventions across more than 50 disease states. These can be a comprehensive medication review, an adherence conversation, a prescriber consultation or patient education. Some jobs pay once when the pharmacist submits the service. Others include a later validation payment after the health plan's claim data confirms that the therapy changed. It is workflow software married to a marketplace, with a small clearinghouse tucked inside.
Its buyers occupy different corners of healthcare. An independent pharmacy may want dispensing software, automatic reminders and new billable services. A chain wants uniform workflow and reporting across thousands of stores. A health plan wants members to take medicine correctly, close care gaps and improve quality ratings. A manufacturer wants a timely way to reach patients who may abandon a prescription. Outcomes sells each party a different benefit while using the same pharmacist-patient encounter as the junction.
The originA roll-up with a forty-year memory
The current brand is new; its plumbing is old. Transaction Data Systems began in 1977 doing high-end data communications for airline reservations and ATMs. A Florida pharmacy looking to automate daily processing helped produce Rx30 around 1980. The company eventually found its lane in pharmacy management software.
The assembly accelerated after GTCR acquired TDS in 2015. Rx30 combined with Oklahoma-based Computer-Rx in 2016, leaving both systems operating independently. By 2021, TDS said it had completed six complementary acquisitions. That year BlackRock Long Term Private Capital bought a majority interest, with GTCR remaining a minority holder.
The most visible price tag arrived in 2022. TDS paid $125 million for PrescribeWellness, the patient-communication and adherence business then owned by Tabula Rasa HealthCare. It was not a venture round. It was a product acquisition: reminders, engagement and clinical communications added to the dispensing systems that pharmacy employees already opened every day.
Then came the identity change. In July 2023, Cardinal Health contributed its Outcomes business to TDS in exchange for a minority stake and a board seat. The assets fit like adjacent pieces: TDS brought Rx30, Computer-Rx and PrescribeWellness; Cardinal's Outcomes brought medication therapy management, engagement, virtual verification, pill counting and financial insight. TDS adopted the Outcomes name. Jude Dieterman, its CEO, stayed in charge.
“For far too long, the industry has been held back by fragmented systems and siloed solutions.”Jude Dieterman, CEO of Outcomes
What failed firstPlatform fatigue met pharmacy math
The first thing to fail was not a company. It was the collection of disconnected tasks around the pharmacist. One product managed the prescription. Another sent the reminder. A separate portal held the clinical opportunity. Vaccine eligibility might require one lookup and state reporting another. Each handoff consumed the scarcest resource in a pharmacy: staff attention.
Outcomes' 2025 Vaccines Module makes the strategy unusually legible. It replaced a legacy PrescribeWellness vaccine tool and moved eligibility, state immunization-system data, documentation and reporting into the same queue used for other clinical work. Save Mor Drugs supervising pharmacist Yogi Kao estimated that handling vaccine tasks in one place saved the pharmacy three hours each week. This is not a moonshot metric. It is exactly the kind of modest weekly recovery that can decide whether a service fits into a short-staffed store.
The same thinking produced Outcomes Insights, formalized for Rx30 users in December 2025. It collects financial, operational, profitability and engagement data into more than 130 reports and dashboards. Pharmacy owners see business metrics; pharmacist profiles emphasize patient information. The data arrives about two hours after processing, not instantly. That small caveat is healthy. Pharmacy operations are messy, and “real time” is too often a marketing costume.
Why it is differentThe bundle is not the moat. The loop is.
Pharmacy owners can buy capable management systems from RedSail, PioneerRx, Liberty Software, PrimeRx and others. They can also assemble separate tools for voice calls, reconciliation, patient messaging or telepharmacy. Outcomes' distinction is the closed loop: prescription data identifies a patient, clinical logic suggests an action, a sponsor funds it, the pharmacist performs it and subsequent claims can validate it.
That loop creates a practical flywheel. More connected pharmacies give payers and manufacturers greater reach. More sponsored opportunities give pharmacies another reason to participate. More completed work produces data about engagement and outcomes. During 2024, the company said its programs returned more than $180 million to pharmacies. In March 2025 alone, the network recorded 475,000 services in one week.
The newest partnerships widen the loop. Asembia embedded specialty-drug support so a patient facing an access problem can reach its services without leaving the pharmacy journey. Walgreens worked on medication reconciliation after hospital discharge. CVS tested different ways to fit comprehensive reviews into retail workflow. Walmart has described rolling out pill identification, counting and visual verification technology developed with Outcomes. These are not just customer logos. Each one adds a job the pharmacy can do without asking staff to start from a blank screen.
What changed the betFrom selling tools to arranging work
The acquisition trail shows the change in conviction. Owning a dispensing system made TDS useful. Adding Computer-Rx created scale. PrescribeWellness added a conversation layer. Cardinal's Outcomes platform added sponsored clinical programs and a payment network. The company moved from selling software that records pharmacy work to arranging higher-value work among organizations that rarely share the same incentives.
Its business model follows that architecture. Pharmacies pay for management software and optional modules. Payers and manufacturers fund programs. Outcomes handles targeting, contracting, documentation, reporting and payments. Exact prices and financials are private, so the cleanest public measure is money returned to pharmacies rather than Outcomes' own revenue.
Put the new action inside the tool people already use. A clinical alert in the dispensing queue beats another portal and password.
Pay for verified behavior, not logins. Outcomes can split intervention and validation fees when claims confirm a therapy change.
Give every participant a reason to stay. Pharmacies earn fees, payers pursue quality goals and manufacturers gain a timely channel.
Measure the customer's economics in its own units: hours saved, services completed and dollars returned to the pharmacy.
The boundary conditionsWhere the model stops working
The model is not magic. A clinical opportunity is valuable only if someone has time to act on it. Rural access may make telepharmacy attractive, but thin staffing can also leave queues untouched. State scope-of-practice rules determine which services pharmacists can provide and bill. Poor integration can recreate the platform fatigue Outcomes promises to remove. And a sponsored program disappears if the economics no longer work for the payer or manufacturer.
Do not copy the playbook when
- The core workflow is not used frequently enough to become the natural place for an adjacent task.
- The professional doing the work lacks legal authority, staffing or reimbursement.
- Validation takes longer than the user's cash flow can tolerate.
- Each side of the network can leave without losing meaningful reach, revenue or operating efficiency.
There is also a product risk in the company's history. Rx30 and Computer-Rx remained distinct after their combination, and the Outcomes catalog still reads like the residue of many deals. Integration has become the pitch because integration remains the work. Customers will judge the company less by how many modules sit on the menu than by whether the seams disappear during a busy Monday morning.
Still, Outcomes has found a compelling place in the market. It is not a pharmacy, a health plan or a drug company. It is connective tissue - the software and commercial network that lets each party use the pharmacist's existing relationship with the patient. The company began by helping a pharmacy process a prescription. Its larger opportunity is helping the person behind the counter do something useful before handing over the bag.